Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

Also Read: AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? Core operating income was $4.9 billion, up 29% at constant currency, mainly driven by higher net sales. The core ...

At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So ...

Reports Q4 cash, cash equivalents, and marketable securities as of December 31 were $434.1M. “2024 was a productive year for Olema and we ...

I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therapy ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Novartis also faced patent expirations in 2012 ... In other news… Johnson &amp, Johnson reported better-than-expected Q4 results, while Abbott’s profit fell 35%. Next Friday (1st Feb ...

Novartis beats Q4 earnings consensus as drug sales surge Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer ...

The court ruled that Novartis is not legally compelled to participate in the Medicare Drug Price Negotiation Program. The decision reaffirmed that the program does not constitute excessive fines ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...

Total Revenue (Q4 2024): $88.3 million ... a new drug discovery collaboration and expanded a software agreement with Novartis, enhancing its collaborative and proprietary pipeline.